Summary
The effects of recombinant human interferons α, β and γ (IFN) on the antiproliferative activity of cytarabine in K562 human myeloid leukaemia clonogenic cells were studied in an agar capillary microassay. The addition of IFN-α did not affect the antiproliferative activity of cytarabine in K562 cultures treated with low concentrations of cytarabine (10–50 nM), whereas in those treated with high concentrations (100–150 nM) IFNα increased the IC50 of cytarabine on day 5 from 102 nM to 214 nM, i.e., cytarabine combined with IFNα was about two-fold less potent than cytarabine alone. Similarly, low concentrations of IFNβ and IFNγ did not affect the antiproliferative activity of cytarabine on K562 colonies, but high concentrations of these two interferons: 4×103 U/ml and 104 U/ml respectively, increased the IC50 of cytarabine on day 5 to 304 nM and to 316 nM respectively, i.e. cytarabine combined with IFNβ or IFNγ was about threefold less potent than cytarabine alone. The evaluation of the present negative interactions of interferons with cytarabine is warranted in fresh cells from myeloid leukaemia patients in primary culture.
Abbreviations
- IFN:
-
interferon
References
Aul C, Gattermann N, Schneider W (1991) Treatment of advanced myelodysplastic syndromes with recombinant interferon-α2b. Eur J Haematol 46:11–16
Beran M, Andersson B, Kantarijian N, Rios A, McCredie KB, Freireich EJ, Gutterman JU (1987) Hematologic response of four patients with smoldering acute myelogenous leukemia to partially pure γ interferon. Leukemia 1:52–57
Büchner TH, Hiddemann W (1990) Treatment strategies in acute myeloid leukemia (AML): a first line chemotherapy. Blut 60:61–67
Catalano L, Majolino I, Musto P, Magrin S, Rotoli B (1988) A trial with α interferon in CMML (abstract). Blut 56:C16
Elias L, Crissman HA (1988) Interferon effects upon the adenocarcinoma 38 and HL-60 cell lines: antiproliferative responses and synergistic interactions with halogenated pyrimidine antimetabolites. Cancer Res 48:4868–4873
Elias L, Hoffman R, Boswell S, Tensen L, Bonnem, EM (1987) A trial of recombinant α-interferon in the myelodysplastic syndromes. Leukemia 1:105–110
Gresser I, Maury C, Belardelli F, Maunoury M-T, Machover D (1988) Effectiveness of mouse interferon α/β compared to single agent chemotherapy in increasing survival time of mice after intravenous inoculation of Friend erythroleukaemia cells. J Natl Cancer Inst 880:126–131
Guilhot F, Dreyfus B, Brizard A, Huret JL, Tanzer J (1991) Cytogenetic remissions in chronic myelogenous leukaemia using recombinant human α2b interferon and hydroxyurea with or without low dose cytosine arabinoside. Leuk Lymphoma 4:49–55
Hassan HT (1990) In vitro differentiation induction of human normal and leukaemic myeloid progenitor cells. Doctorate (Ph. D.) Thesis in Haematology, University of Cambridge Clinical School, Cambridge, England
Hassan HT (1991) In vitro interaction between retinoids and cytokines in human myeloid leukaemia cells. Eur J Cancer 27:1182–1183
Hassan HT, Maurer HR (1991a) Synergistic combinations for differentiation therapy of myeloid leukaemia patients. Med Sci Res 19:195–198
Hassan HT, Maurer HR (1991b) Effects of recombinant human cytokines on cytarabine activity in K562 human myeloid leukaemia cells. Chemotherapy 37:441–448
Hassan HT, Rees JKH (1988) Retinoic acid alone and in combination with cytosine arabinoside induces differentiation of human myelomonocytic and monoblastic leukemic cells. Hematol Oncol 6:39–45
Hassan HT, Veit A, Maurer HR (1991) Synergistic interactions between differentiation induction agents in inhibiting the proliferation of HL-60 human myeloid leukaemia cells in clonogenic microassay. J Cancer Res Clin Oncol 117:227–231
Hosoi T, Ozawa K, Ohta M, Okabe T, Urabe A, Takaku F (1985) Recombinant immune interferon inhibits leukemic cell growth by a monocyte-macrophage-mediated mechanism. Exp Hematol 13:597–602
Kafka M, Dvilansky A, Nathan I (1990) Mechanism of interaction between γ interferon and antineoplastic agent on the differentiation of HL-60 promyelocyte leukemia cells. Exp Hematol 18:153–158
Kurzrock R, Talpaz M, Kantarijian H, Walters R, Saks S, Trujillo JM, Gutterman JU (1987) Therapy of chronic myelogenous leukemia with human interferon γ. Blood 70:943–947
Lozzio CB, Lozzio BB (1975) Human chronic myelogenous leukaemia cell line with positive Philadelphia chromosome. Blood 45:321–334
Maiolo AT, Cortelezzi A, Calori R, Polli EE (1990) Recombinant human γ interferon as first line therapy for high risk myelodysplastic syndromes. Leukemia 4:480–485
Montserrat E, Villamor N, Urbano-Ispizue A, Ribera JM, Lazano M, Vives-Corrons JL, Rozman C (1991) Treatment of early stage-B chronic lymphocytic leukaemia with α-2b interferon after chlorambucil reduction of the tumour mass. Ann Haematol 63:15–19
Mowshowitz SL, Chin-Bow ST, Smith GD (1982) Interferon and cis-DDP: combination chemotherapy for P388 leukaemia in CDF1 mice. J Interferon Res 2:587–591
Ogawa M, Yoshida Y, Moriyama Y (1988) Phase II clinical trial of recombinant human interferon γ on myelodysplastic syndromes. Third International Congress of Myelodysplasia. Blut 56:c21, 12A
Ozer H (1988) Biotherapy of chronic myelogenous leukaemia with interferon. Semin Oncol 15:14–20
Rowley PT, Wilhelm BM, Farley BA, LeBalla S (1981) Inducers of erythroid differentiation in K562 human leukemia cells. Exp Hematol 9:32–37
Slater LM, Wetzel MW, Cesario T (1981) Combined interferon-antimetabolite therapy of murine L1210 leukemia. Cancer 48:5–9
Sutlerland JA, Turner AR, Mannoni P, McGann LE, Ture JM (1986) Differentiation of K562 leukaemic cells along erythroid, nacrophage, granulocyte and megakaryocyte lineages. J Biol Response Mod 5:250–262
Tafuri A, Andreeff (1990) Kinetic rationale for cytokine-induced recruitment of myeloblastic leukemia followed by cycle specific chemotherapy in vitro. Leukemia 4:826–834
Talpaz M, Kantarijian H, Kurzrock R, Trujillo JM, Gutterman JU (1991) Interferon-α produces sustained cytogenetic responses in chronic myeloid leukaemia Philadelphia chromosome positive patients. Ann Intern Med 114:532–537
Wadler S, Schwartz EL (1990) Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies. Cancer Res 50:3473–3486
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Maurer, H.R., Hassan, H.T., Tsiriyotis, C. et al. Recombinant human interferonsα,β andγ reduce the antiproliferative action of cytarabine in K562 human myeloid leukaemia clonogenic cells. J Cancer Res Clin Oncol 118, 329–333 (1992). https://doi.org/10.1007/BF01294435
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01294435